

Summary Report of Financial Results for the FY ended December 2012

February 08, 2013

Company Name: Carna Biosciences, Inc.
 Stock exchange listing: Osaka Securities Exchange (JASDAQ Glowth)
 Stock Code: 4572
 URL: <http://www.carnabio.com>
 Representative: Kohichiro Yoshino, President
 Contact: Norio Aikawa, Director
 TEL +81-78-302-7039

(Rounding down to the nearest million yen)

1. Consolidated results for the FY2012 (January 1, 2012 - December 31, 2012)

(1) Business Results (Consolidated) (% indicates increases or decreases from the previous year)

	Total Revenue		Operating income		Ordinary income		Net income	
	million yen	%	million yen	%	million yen	%	million yen	%
FY2012	510	-13.8	-457	-	-442	-	-449	-
FY2011	592	3.6	-393	-	-340	-	-361	-

	Net income per share	Net income per share (diluted)
	yen	yen
FY2012	-7328.33	-
FY2011	-6159.97	-

Note: Net income per share of FY2011 and 2012(Diluted): No statement - We had net loss per share even though we had diluted shares.

(2) Financial Condition (Consolidated)

	Total assets	Net assets	Equity ratio	Net assets per share
	million yen	million yen	%	Yen
FY2012	1,116	880	78.9	12,098.79
FY2011	1,317	1,019	77.4	17,359.64

(3) Cash Flows (Consolidated)

	Operating activities	Investing activities	Financing activities	Balance of cash and cash equivalents
	million yen	million yen	million yen	million yen
FY2012	-425	-37	241	611
FY2011	-350	-7	16	831

2. Cash Dividends

(criterion)	Dividends per share				
	End of 1 st quarter period	End of 2 nd quarter period	End of 3 rd quarter period	End of FY	FY
	yen	yen	yen	yen	yen
FY2011	-	0.00	-	0.00	0.00
FY2012	-	0.00	-	0.00	0.00
FY2013 (forecast)	-	0.00	-	0.00	0.00

3. Consolidated forecast for FY2013 (January 1, 2013 - December 31, 2013)

(% indicates increases or decreases from the previous year)

	Total revenue		Operating income		Ordinary income		Net income		Net income per share
	million yen	%	million yen	%	million yen	%	million yen	%	Yen
FY2013	1,155	126.1	4	-	28	-	23	-	316.20

*Disclaimer regarding appropriate use of forecasts and related points of note

1. The above-mentioned forecasts are based on the information available on the date of release of these materials and on various assumptions made on the date of release of these material including uncertain factors and may affect future earnings. Actual operating results may differ significantly from those forecasts as a consequence of various factors.
2. The forecasted net income per share above is calculated based on 72,800 issued shares.